MET and lung carcinoma: In addition to EGFR, a number of other tyrosine kinases have been proposed as therapeutic targets in lung cancer, including MET, insulin-like growth factor receptors (IGFR), SRC kinases, fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptors (PDGFR), anaplastic lymphoma kinase (ALK), and EPH receptors [4], [5], [6], [7], [8], [9], [10], [11], [12].